André Veillette

18PUBLICATIONS
61CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Characterisation of biological macromoleculesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Feb 11, 2026
SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer.

Bin Li, Ming-Chao Zhong, Cristian Camilo Galindo

|Dec 08, 2025
Targeting phagocytosis checkpoints for cancer immunotherapy.

André Veillette, Jiaxin Li, Cristian Camilo Galindo

|Oct 10, 2025
Anticancer immune responses are hindered by cis interaction of inhibitory checkpoint SIRPα.

Zhenghai Tang, Ming-Chao Zhong, Jin Qian

|Sep 30, 2025
CD2 and its ligands are involved in development and activation of MAIT cells.

Kaiwen Zhu, Jiayu Dou, Bin Li

|Sep 26, 2025
Inhibitory immune checkpoints in cancer immunotherapy.

Zhenghai Tang, André Veillette

|Nov 09, 2023
CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.

Zhenghai Tang, Ming-Chao Zhong, Jin Qian

Pageof 3

Frequent Collaborators

5 joint publications

Jin Qian

5 joint publications

Cristian Camilo Galindo

4 joint publications

Bin Li

3 joint publications

Zhenghai Tang